OPKO Health, Inc. (NASDAQ:OPK) CEO Purchases $162,000.00 in Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 100,000 shares of the stock in a transaction dated Thursday, November 14th. The stock was bought at an average price of $1.62 per share, for a total transaction of $162,000.00. Following the completion of the purchase, the chief executive officer now owns 211,612,405 shares in the company, valued at approximately $342,812,096.10. This trade represents a 0.05 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, November 8th, Phillip Md Et Al Frost purchased 280,183 shares of OPKO Health stock. The stock was bought at an average price of $1.50 per share, for a total transaction of $420,274.50.

OPKO Health Trading Up 1.2 %

Shares of NASDAQ OPK opened at $1.64 on Friday. OPKO Health, Inc. has a 1-year low of $0.85 and a 1-year high of $1.75. The company has a 50-day moving average of $1.52 and a two-hundred day moving average of $1.43. The company has a market cap of $1.12 billion, a PE ratio of -8.63 and a beta of 1.65. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. CIBC Asset Management Inc lifted its stake in shares of OPKO Health by 79.1% during the second quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 8,978 shares during the period. Virtu Financial LLC acquired a new position in OPKO Health during the 1st quarter valued at about $26,000. FMR LLC boosted its stake in shares of OPKO Health by 103.6% in the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 11,089 shares during the last quarter. Algert Global LLC acquired a new stake in shares of OPKO Health during the 2nd quarter worth approximately $44,000. Finally, Orion Portfolio Solutions LLC bought a new stake in shares of OPKO Health during the third quarter worth approximately $45,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on OPK shares. HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a research note on Thursday, September 26th. Barrington Research reaffirmed an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a report on Friday, November 8th. StockNews.com raised OPKO Health to a “sell” rating in a report on Saturday, July 27th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $3.00 price target on shares of OPKO Health in a report on Tuesday, September 17th.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.